Skip to main content
. Author manuscript; available in PMC: 2023 Sep 1.
Published in final edited form as: Am J Med Genet A. 2022 Jun 9;188(9):2672–2683. doi: 10.1002/ajmg.a.62860

Table 1.

Patient Demographic and Clinical Characteristics

All Schwannomatosis Patients (n=97) Confirmed Schwannomatosis Patients (n=64) Probable Schwannomatosis Patients (n=33)
Female 49 (50.5%) 30 (46.9%) 19 (57.6%)
Familial Disease 15 (15.4%) 11 (17.2%) 4 (12%)
Anatomically Limited Disease 20 (20.6%) 14 (21.9%) 6 (18%)
Age at First Symptom, median (range) 32.9 years (5.1 – 68.3 years) 30.8 years (5.1 – 64.1 years) 39.7 years (12.5 – 68.3 years)
First Symptom Type
 Pain 51 (52.6%) 34 (53.1%) 17 (51.5%)
 Palpable Mass 10 (10.3%) 7 (10.9%) 3 (9.1%)
 Neurological Symptoms 4 (4.1%) 0 (0.0%) 4 (12.1%)
 Pain and Palpable Mass 11 (11.3%) 6 (9.4%) 5 (15.2%)
 Pain and Neurological Symptoms 8 (8.2%) 7 (10.9%) 1 (3.0%)
 Other 1 (1.0%) 1 (1.6%) 0 (0.0%)
 Unknown 2 (2.1%) 2 (3.1%) 0 (0.0%)
 N/A: Asymptomatic 10 (10.3%) 7 (10.9%) 3 (9.1%)
First Symptom Frequency
 Constant 33 (34.0%) 21 (32.8%) 12 (36.4%)
 Intermittent 29 (29.9%) 18 (28.1%) 11 (33.3%)
 Unknown 25(25.8%) 18 (28.1%) 7 (21.2%)
 N/A: Asymptomatic 10 (10.3%) 7 (10.9%) 3 (9.1%)
Initial Imaging Workup
 Single tumor discovered 54 (55.7%) 38 (59.4%) 16 (48.5%)
 Two or more tumors discovered 40 (41.2%) 25 (39.1%) 15 (45.4%)
 Unknown 2 (2.1%) 1 (1.6%) 1 (3.0%)
 N/A – no tumors discovered 1 (1.0%) 0 (0%) 1 (3.0%)

Footnotes:

Neurological symptoms included numbness, paresthesias, muscle weakness and hypophonia.

Other symptom was severe coughing spells due to a schwannoma compressing the esophagus.